Developing as a promising advance in the struggle against obesity, the drug is attracting considerable buzz. This treatment combines the action of two recognized GLP-1 binding agonists, liraglutide, with an new glucose-dependent incretin component. Initial patient findings have shown significant weight loss in people with obesity , possibly offeri